Hidradenitis Suppurativa

Dermatology·MeSH: Hidradenitis Suppurativa

Prevalence

1000.0 / 100K

Incidence

100.0 / 100K/yr

32 drugs in development·16 companies·45 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
abrilada	PFIZER INC (PFE)

Phase 3(6)

Phase 2(18)

Drug	Company
abdakibart	Avalo Therapeutics, Inc. (AVTX)
ATI-450	Aclaris Therapeutics, Inc. (ACRS)
AVTX-009	Avalo Therapeutics, Inc. (AVTX)
avtx-009 regimen 1	Avalo Therapeutics, Inc. (AVTX)
avtx-009 regimen 2	Avalo Therapeutics, Inc. (AVTX)
bimekizumab	POINT Biopharma Global Inc. (PNT)
brivekimig	Sanofi (SNY)
brivekimig	Sanofi (SNY)
izokibep	ACELYRIN, Inc. (SLRN)
KT-474/SAR444656	Kymera Therapeutics, Inc. (KYMR)
sar442970	Sanofi (SNY)
SAR442970	Sanofi (SNY)
sar444656	Sanofi (SNY)
sar445399	Sanofi (SNY)
SAR445399	Sanofi (SNY)
tibulizumab dose a	Zura Bio Ltd (ZURA)
tibulizumab dose b	Zura Bio Ltd (ZURA)
Zunsemetinib (ATI-450)	Aclaris Therapeutics, Inc. (ACRS)

Phase 1(4)

Drug	Company
PN-881	Protagonist Therapeutics, Inc (PTGX)
sbt777101	Bolt Biotherapeutics, Inc. (BOLT)
sbt777101	SAB BIOTHERAPEUTICS, INC. (SABS)
Sonelokimab	MoonLake Immunotherapeutics (MLTX)

Preclinical(1)

Drug	Company
AVTX-913	Avalo Therapeutics, Inc. (AVTX)

Phase 4(2)

Drug	Company
Anifrolumab	ASTRAZENECA PLC (AZN)
secukinumab s.c	Novartis AG (NVS)

BioSniper tracks 32 drugs in development for Hidradenitis Suppurativa across 16 companies.

There are 45 clinical trials targeting Hidradenitis Suppurativa tracked by BioSniper.

The estimated prevalence of Hidradenitis Suppurativa is approximately 1000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.